NYSEAMERICAN:IBIO - Ibio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.86 +0.01 (+1.18 %) (As of 02/15/2019 04:00 PM ET)Previous Close$0.86Today's Range$0.85 - $0.9052-Week Range$0.50 - $3.50Volume26,883 shsAverage Volume65,741 shsMarket Capitalization$16.07 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York. Receive IBIO News and Ratings via Email Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:IBIO Previous SymbolNASDAQ:IBIO CUSIPN/A Webwww.ibioinc.com Phone+1-302-3550650Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees54 Outstanding Shares18,687,000Market Cap$16.07 million OptionableNot Optionable Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions What is Ibio's stock symbol? Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO." When did Ibio's stock split? How did Ibio's stock split work? Shares of Ibio reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split. Has Ibio been receiving favorable news coverage? News coverage about IBIO stock has trended somewhat negative on Saturday, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ibio earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. Are investors shorting Ibio? Ibio saw a decline in short interest during the month of January. As of January 31st, there was short interest totalling 470,437 shares, a decline of 7.2% from the January 15th total of 506,796 shares. Based on an average daily trading volume, of 54,243 shares, the short-interest ratio is presently 8.7 days. Currently, 2.6% of the shares of the company are short sold. View Ibio's Current Options Chain. Who are some of Ibio's key competitors? Some companies that are related to Ibio include Helix Biopharma (HBP), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Imugene (IMU), Antibe Therapeutics (ATE), Biotron (BIT), Asterias Biotherapeutics (AST), Noxopharm (NOX), Oncolytics Biotech (ONC), Zelda Therapeutics (ZLD), Immunoprecise Antibodies (IPA), DiaMedica Therapeutics (DMA), Navidea Biopharmaceuticals (NAVB), Ceapro (CZO) and Galena Biopharma (SLS). Who are Ibio's key executives? Ibio's management team includes the folowing people: Mr. Robert B. Kay, Exec. Chairman & CEO (Age 79)Mr. Robert L. Erwin, Pres (Age 66)Mr. James P. Mullaney CPA, CPA, Chief Financial Officer (Age 48)Mr. Terence E. Ryan, Chief Scientific Officer (Age 64)Dr. Renato Lobo, Chief Medical Officer How do I buy shares of Ibio? Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ibio's stock price today? One share of IBIO stock can currently be purchased for approximately $0.86. How big of a company is Ibio? Ibio has a market capitalization of $16.07 million. Ibio employs 54 workers across the globe. What is Ibio's official website? The official website for Ibio is http://www.ibioinc.com/. How can I contact Ibio? Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650. MarketBeat Community Rating for Ibio (NYSEAMERICAN IBIO)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 80 (Vote Outperform)Underperform Votes: 63 (Vote Underperform)Total Votes: 143MarketBeat's community ratings are surveys of what our community members think about Ibio and other stocks. Vote "Outperform" if you believe IBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: What is the Bid-Ask Spread?